• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Tools+
    • EvidencePulse™
    • HypeCheck™
    • NPI Registry Lookup
    • RVU Search
  • Pharma
  • AI Roundup
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • My account
    • Cart
    • Sign-in
2 Minute Medicine
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Tools+
    • EvidencePulse™
    • HypeCheck™
    • NPI Registry Lookup
    • RVU Search
  • Pharma
  • AI Roundup
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • My account
    • Cart
    • Sign-in
SUBSCRIBE
2 Minute Medicine
Subscribe
EvidencePulse™ by 2 Minute Medicine 2026 evidence scan 3 reports You asked top stroke trials 2026 Synthesizing medical evidence... Top 2026 stroke trial results: OCEANIC — ischemic stroke: 6.2% vs 8.4% OPTION* — mRS 0–1: 43.6% vs 34.2% ORIENTAL* — mRS 0–2: 58.6% vs 46.6% *Higher sICH in intervention arms Participants randomizedN OCEANIC 12,327 OPTION 570 ORIENTAL 564 Ask about guidelines or landmark trials... ↑ Try EvidencePulse™ Ask the evidence.
Get the signal.
Try it now → Physician-trained medical AI by 2 Minute Medicine
Home All Specialties Chronic Disease

Healthier lifestyle linked with longer telomeres in benign prostate cancer

bys25qthea
September 24, 2013
in Chronic Disease, Oncology, Urology
Reading Time: 4 mins read
Androgen deprivation in prostate cancer: intermittent may compromise survival
Share on FacebookShare on Twitter

Image: PD

1. Men with biopsy-verified, benign prostate cancer who underwent healthy lifestyle changes over a five-year period had longer telomeres than men who did not.

2. There was a positive correlation between the degree of adherence to the regimen and the amount of change in telomere length from baseline.

Evidence Rating Level: 2 (Good)

Study Rundown: Studies suggest that people with shorter telomeres are at an increased risk for many diseases, including several types of cancer. While it is known that differences in the length of our telomeres are partially attributable to genetic variation, the role played by environmental factors is decidedly less clear. This study presented a correlation between lifestyle modifications and telomere length in men diagnosed with low-risk prostate cancer. The authors compared men who received active surveillance plus lifestyle changes to a control group that underwent active surveillance only. After five years, telomere length and telomerase activity were measured and patients who had followed the healthy lifestyle regimen had longer telomeres compared to those who had not (p=0.03). However, there was no significant difference in telomerase activity between the two groups (p=0.64). Interestingly, when data from all participants were analyzed together, a positive correlation was observed between the degree of healthy lifestyle change and relative telomere length. This study had small sample sizes in both groups, which limits the generalizability of the authors’ findings. Further, this was not a randomized study, thus raising important questions about the influence of bias at multiple steps in the study’s progression. Ultimately, as correlation does not equate causation, studies on possible mechanisms behind the observed effects are needed. It is also clear that larger, randomized controlled trials are needed to provide stronger evidence in favor of the authors’ conclusions.

Click to read the study in The Lancet Oncology

RELATED REPORTS

Enzalutamide (Xtandi) and abiraterone (Zytiga) may have similar effectiveness in metastatic castration-sensitive prostate cancer

Stockholm3 outperforms PSA for detecting significant prostate cancer 

Pfizer’s Talzenna combo significantly delays prostate cancer progression

Relevant Reading: Genetic and Lifestyle Influence on Telomere Length and Subsequent Risk of Colon Cancer in a Case Control Study

Study co-author, Professor Dean Ornish, M.D., of the University of California San Francisco talks to 2 Minute Medicine:

“The implications of this relatively small pilot study may go beyond men with prostate cancer. If validated by large-scale randomized controlled trials, these comprehensive lifestyle changes may significantly reduce the risk of a wide variety of diseases and premature mortality. Our genes, and our telomeres, are a predisposition, but they are not necessarily our fate.”

In-Depth [prospective cohort study]: 64 patients with pathology-confirmed prostate cancer plus a Gleason score of 6 or lower, a PSA of 10 µg/L or lower and a stage T1 or T2a tumor (on a TNM staging system) were included in this study. 30 patients underwent active surveillance plus life style changes consisting of four components: a low-fat, low-carbohydrate diet, regular aerobic exercise, stress reduction activities, and social support group sessions. The amount of participation in each of these activities was used to compute lifestyle index scores for each patient. 34 patients underwent active surveillance only. Telomere length was measured via qPCR relative to a standard DNA sequence, reported as telomere to single-copy gene ratio (T/S). Telomerase activity was measured in patients’ PBMCs and compared to HEK 293T cells (positive control). Out of the initial population, the baseline PBMC samples of 10 men in the intervention group and 25 men in the control group were sufficient enough to merit inclusion in the follow-up analysis.

The authors found that the intervention group’s telomere length increased by a median of 0.06 T/S units (IQR -0.05 to 0.11), while the control group’s telomere length decreased by a median of -0.03 T/S units (IQR -0.05 to 0.03) after five years (p=0.03). The median lifestyle index score was predictably higher in the intervention group (increase of 0.22 units, IQR 0.13 to 0.36) than in the control group (decrease of 0.06 units, IQR -0.17 to 0.08) after five years (p=0.02). When the telomere lengths and lifestyle scores of both groups were analyzed together, a positive correlation between the two measures was observed; for every percentage point increase in lifestyle score, the average telomere length increased by 0.07 T/S units (p=0.005). However, the median change in telomerase activity after five years was not significantly different between the two groups (p=0.64).

By Nick Woolf and Mimmie Kwong

More from this author: MERS remains poorly understood, deadly, Among HIV-positive infants, early protease inhibitor-based treatment effective

© 2013 2minutemedicine.com. All rights reserved. No works may be reproduced without expressed written consent from 2minutemedicine.com. Disclaimer: We present factual information directly from peer reviewed medical journals. No post should be construed as medical advice and is not intended as such by the authors, editors, staff or by 2minutemedicine.com. PLEASE SEE A HEALTHCARE PROVIDER IN YOUR AREA IF YOU SEEK MEDICAL ADVICE OF ANY SORT.

Tags: prostate cancer
Previous Post

Recommendations for intrapartum management of TOLAC

Next Post

The CARE trial: Statins in coronary artery disease [Classics Series]

RelatedReports

Radiation plus hormone therapy may improve prostate cancer survival
Chronic Disease

Enzalutamide (Xtandi) and abiraterone (Zytiga) may have similar effectiveness in metastatic castration-sensitive prostate cancer

July 22, 2026
Patient-reported outcomes differ significantly based on treatment in prostate cancer: The ProtecT trial
Oncology

Stockholm3 outperforms PSA for detecting significant prostate cancer 

June 22, 2026
Radiation plus hormone therapy may improve prostate cancer survival
Oncology

Pfizer’s Talzenna combo significantly delays prostate cancer progression

April 9, 2026
2 Minute Medicine: Pharma Roundup: Price Hikes, Breakthrough Approvals, Legal Showdowns, Biotech Expansion, and Europe’s Pricing Debate [May 12nd, 2025]
Endocrinology

2 Minute Medicine: Pharma Roundup – Pfizer’s Talzenna delays prostate cancer progression, apixaban lowers VTE bleeding risk, Lilly’s retatrutide hits Phase III metabolic targets, and FDA warns Novo Nordisk over safety reporting violations [March 2026]

March 30, 2026
Next Post
Classics Series, Landmark Trials in Medicine

The CARE trial: Statins in coronary artery disease [Classics Series]

Hypercortisolemia in ICU patients is due to reduced cortisol metabolism, not increased production

Perceived futility of treatments in the ICU dependent on key patient factors

Arsenic exposure linked with cardiovascular disease and mortality

Arsenic exposure linked with cardiovascular disease and mortality

EvidencePulse™ by 2 Minute Medicine 2026 evidence scan 3 reports You asked top stroke trials 2026 Synthesizing medical evidence... Top 2026 stroke trial results: OCEANIC — ischemic stroke: 6.2% vs 8.4% OPTION* — mRS 0–1: 43.6% vs 34.2% ORIENTAL* — mRS 0–2: 58.6% vs 46.6% *Higher sICH in intervention arms Participants randomizedN OCEANIC 12,327 OPTION 570 ORIENTAL 564 Ask about guidelines or landmark trials... ↑ Try EvidencePulse™ Ask the evidence.
Get the signal.
Try it now → Physician-trained medical AI by 2 Minute Medicine

2MM+ All Access

Full details →
$4.99 /month

5-day free trial · cancel anytime

  • ✓100+ physician-written reports
  • ✓EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters
Start 5-day free trial

Then $4.99/month. Manage renewal in your account.

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • The rate of urethrocutaneous fistula following caudal and penile blocks for hypospadias repair may be similar
  • Adjuvant chemotherapy not linked to improved outcomes in localized appendiceal adenocarcinoma
  • Deep learning model improved cancer recurrence prediction for pediatric glioma using serial imaging
License Content
Terms of Use | Disclaimer
Cookie Policy
Cleantalk Pixel
2MM+ All Access Full details →

The medical literature, distilled daily.

Monthly plan selected: $4.99 /month.

$4.99/month

5-day free trial · cancel anytime

Start 5-day free trial

Then $4.99/month. Manage renewal in your account.

Yearly plan selected: $49.90 /year.

$49.90/year

2 months free · only $4.16/month

Start 5-day free trial

Then $49.90/year. Manage renewal in your account.

Membership benefits

  • ✓100+ physician-written reports
  • ✓AI EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters

Already a member? Sign in

  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Tools
    • EvidencePulse™
    • HypeCheck™
    • NPI Registry Lookup
    • RVU Search
  • Pharma
  • AI Roundup
  • The Scan
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • My account
    • Cart
    • Sign-in
No Result
View All Result

© 2026 2 Minute Medicine, Inc. - Physician-written medical news.